Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis

Jungsoo Lee, Hemin Lee, Seongmin Noh, Byung Gi Bae, Jung U. Shin, Chang Ook Park, Kwanghoon Lee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: In extrinsic atopic dermatitis (AD), house dust mites (HDM) play a role in eliciting or aggravating allergic lesions. The nature of skin inflammation in AD has raised a growing interest in allergen-specific immunotherapy (SIT). Thus, we assessed clinical improvement and laboratory parameters for evaluation of the benefit of long-term SIT. Materials and Methods: A total of 217 AD patients who were treated with SIT for at least 3 years were retrospectively assessed, by using their investigator global assessment, pruritus scores, loss of sleep (LOS), total serum IgE, and eosinophil counts collected. Patients were additionally classified into subgroups according to age, initial AD severity and mono- or multi-sensitization to include different individual factors in the evaluation of SIT efficacy. Lastly, we compared laboratory data of good responders to SIT with that of poor responders to SIT. Results: Improvement after SIT therapy was observed in 192 out of 217 patients (88.4%). Among these patients, 138 (63.5%) achieved excellent, near-complete or complete clinical remission. Significant reduction of pruritus, LOS, and the mean value of total serum IgE were observed (p<0.01). Better outcome was found in patients younger than 12 years of age (p=0.024). Patients with moderate to severe AD showed better treatment outcomes (p=0.036). Patients sensitized only to HDM had the better response to treatment, but SIT was also effective in multi-sensitized groups (p=1.051). No significant differences in baseline laboratory results were observed between good and poor responders (p>0.05). Conclusion: We emphasize the usefulness of long-term HDM SIT as a disease-modifying therapy for AD.

Original languageEnglish
Pages (from-to)393-398
Number of pages6
JournalYonsei medical journal
Volume57
Issue number2
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Pyroglyphidae
Atopic Dermatitis
Immunotherapy
Pruritus
Immunoglobulin E
Sleep
Immunologic Desensitization
Serum
Eosinophils
Research Personnel
Inflammation
Skin
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Jungsoo ; Lee, Hemin ; Noh, Seongmin ; Bae, Byung Gi ; Shin, Jung U. ; Park, Chang Ook ; Lee, Kwanghoon. / Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis. In: Yonsei medical journal. 2016 ; Vol. 57, No. 2. pp. 393-398.
@article{5e681bdbe8e0404f9f895eebb58fdd2b,
title = "Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis",
abstract = "Purpose: In extrinsic atopic dermatitis (AD), house dust mites (HDM) play a role in eliciting or aggravating allergic lesions. The nature of skin inflammation in AD has raised a growing interest in allergen-specific immunotherapy (SIT). Thus, we assessed clinical improvement and laboratory parameters for evaluation of the benefit of long-term SIT. Materials and Methods: A total of 217 AD patients who were treated with SIT for at least 3 years were retrospectively assessed, by using their investigator global assessment, pruritus scores, loss of sleep (LOS), total serum IgE, and eosinophil counts collected. Patients were additionally classified into subgroups according to age, initial AD severity and mono- or multi-sensitization to include different individual factors in the evaluation of SIT efficacy. Lastly, we compared laboratory data of good responders to SIT with that of poor responders to SIT. Results: Improvement after SIT therapy was observed in 192 out of 217 patients (88.4{\%}). Among these patients, 138 (63.5{\%}) achieved excellent, near-complete or complete clinical remission. Significant reduction of pruritus, LOS, and the mean value of total serum IgE were observed (p<0.01). Better outcome was found in patients younger than 12 years of age (p=0.024). Patients with moderate to severe AD showed better treatment outcomes (p=0.036). Patients sensitized only to HDM had the better response to treatment, but SIT was also effective in multi-sensitized groups (p=1.051). No significant differences in baseline laboratory results were observed between good and poor responders (p>0.05). Conclusion: We emphasize the usefulness of long-term HDM SIT as a disease-modifying therapy for AD.",
author = "Jungsoo Lee and Hemin Lee and Seongmin Noh and Bae, {Byung Gi} and Shin, {Jung U.} and Park, {Chang Ook} and Kwanghoon Lee",
year = "2016",
month = "3",
day = "1",
doi = "10.3349/ymj.2016.57.2.393",
language = "English",
volume = "57",
pages = "393--398",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "2",

}

Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis. / Lee, Jungsoo; Lee, Hemin; Noh, Seongmin; Bae, Byung Gi; Shin, Jung U.; Park, Chang Ook; Lee, Kwanghoon.

In: Yonsei medical journal, Vol. 57, No. 2, 01.03.2016, p. 393-398.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis

AU - Lee, Jungsoo

AU - Lee, Hemin

AU - Noh, Seongmin

AU - Bae, Byung Gi

AU - Shin, Jung U.

AU - Park, Chang Ook

AU - Lee, Kwanghoon

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: In extrinsic atopic dermatitis (AD), house dust mites (HDM) play a role in eliciting or aggravating allergic lesions. The nature of skin inflammation in AD has raised a growing interest in allergen-specific immunotherapy (SIT). Thus, we assessed clinical improvement and laboratory parameters for evaluation of the benefit of long-term SIT. Materials and Methods: A total of 217 AD patients who were treated with SIT for at least 3 years were retrospectively assessed, by using their investigator global assessment, pruritus scores, loss of sleep (LOS), total serum IgE, and eosinophil counts collected. Patients were additionally classified into subgroups according to age, initial AD severity and mono- or multi-sensitization to include different individual factors in the evaluation of SIT efficacy. Lastly, we compared laboratory data of good responders to SIT with that of poor responders to SIT. Results: Improvement after SIT therapy was observed in 192 out of 217 patients (88.4%). Among these patients, 138 (63.5%) achieved excellent, near-complete or complete clinical remission. Significant reduction of pruritus, LOS, and the mean value of total serum IgE were observed (p<0.01). Better outcome was found in patients younger than 12 years of age (p=0.024). Patients with moderate to severe AD showed better treatment outcomes (p=0.036). Patients sensitized only to HDM had the better response to treatment, but SIT was also effective in multi-sensitized groups (p=1.051). No significant differences in baseline laboratory results were observed between good and poor responders (p>0.05). Conclusion: We emphasize the usefulness of long-term HDM SIT as a disease-modifying therapy for AD.

AB - Purpose: In extrinsic atopic dermatitis (AD), house dust mites (HDM) play a role in eliciting or aggravating allergic lesions. The nature of skin inflammation in AD has raised a growing interest in allergen-specific immunotherapy (SIT). Thus, we assessed clinical improvement and laboratory parameters for evaluation of the benefit of long-term SIT. Materials and Methods: A total of 217 AD patients who were treated with SIT for at least 3 years were retrospectively assessed, by using their investigator global assessment, pruritus scores, loss of sleep (LOS), total serum IgE, and eosinophil counts collected. Patients were additionally classified into subgroups according to age, initial AD severity and mono- or multi-sensitization to include different individual factors in the evaluation of SIT efficacy. Lastly, we compared laboratory data of good responders to SIT with that of poor responders to SIT. Results: Improvement after SIT therapy was observed in 192 out of 217 patients (88.4%). Among these patients, 138 (63.5%) achieved excellent, near-complete or complete clinical remission. Significant reduction of pruritus, LOS, and the mean value of total serum IgE were observed (p<0.01). Better outcome was found in patients younger than 12 years of age (p=0.024). Patients with moderate to severe AD showed better treatment outcomes (p=0.036). Patients sensitized only to HDM had the better response to treatment, but SIT was also effective in multi-sensitized groups (p=1.051). No significant differences in baseline laboratory results were observed between good and poor responders (p>0.05). Conclusion: We emphasize the usefulness of long-term HDM SIT as a disease-modifying therapy for AD.

UR - http://www.scopus.com/inward/record.url?scp=84956933253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956933253&partnerID=8YFLogxK

U2 - 10.3349/ymj.2016.57.2.393

DO - 10.3349/ymj.2016.57.2.393

M3 - Article

VL - 57

SP - 393

EP - 398

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 2

ER -